Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2017 pubmed 61 citations

Cathelicidin antimicrobial peptide from Alligator mississippiensis has antibacterial activity against multi-drug resistant Acinetobacter baumanii and Klebsiella pneumoniae.

Barksdale. Stephanie M SM; Hrifko. Evelyn J EJ; van Hoek. Monique L ML

Key Findings

  • The alligator cathelicidin peptide (and two shorter fragments) kills multi‑drug‑resistant Gram‑negative bacteria in lab tests.
  • The peptides disrupt bacterial membranes and remain active even in salty conditions.
  • They show little to no toxicity toward human lung cells and red blood cells at concentrations up to 300 µg/mL.

Practical Outcomes

  • For now, the main takeaway is that this alligator‑derived peptide looks promising as a future antimicrobial therapy, especially against resistant infections. It isn’t ready for personal use or supplementation, but the safety profile suggests it could be developed into a drug with minimal side effects. Biohackers should watch for later studies that might translate this into oral or topical products.

Summary

Scientists found a natural antimicrobial protein from alligator blood that can kill tough, drug‑resistant bacteria like Acinetobacter and Klebsiella. The peptide works by punching holes in bacterial membranes, isn’t killed by salt, and doesn’t harm human cells or red blood cells at the tested doses. It could become a new kind of anti‑infection drug, but it’s still early‑stage research.

Abstract

Alligator mississippiensis (American alligator), a member of order Crocodilia, lives in bacteria-laden environments but is not often known to succumb to bacterial infections. Their serum has been shown to have antibacterial activity beyond that of human serum, and it is believed that this activity is partially due to cationic antimicrobial peptides (CAMPs). CAMPs are produced by many organisms as part of the innate immune system. CAMPs are attractive possible therapies against multi-drug resistant bacteria, such as those found in biofilm-infected war wounds, because they seldom cause genetic resistance in bacteria and are effective against antibiotic resistant bacteria. In this work, we identified, synthesized, and characterized a cathelicidin and two shorter fragments from the American alligator. We discovered the cathelicidin using Basic Local Alignment Search Tool (BLAST) alignment and by comparing A. mississippiensis expressed sequence tags (ESTs) with propeptide cathelicidins of other reptiles. We analyzed the structure using bioinformatics tools and circular dichroism and predicted that the full-length cathelicidin peptide has a mixed structure, with an N-terminal α-helix and a center Pro hinge. In minimal inhibitory concentration (MIC) assays, it was determined that the cathelicidin and the two shorter fragments have strong activity against multiple Gram-negative bacteria, including clinical isolates of multi-drug resistant (MDR) Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae. Using the ethidium bromide uptake assay, it was found that these peptides permeabilize the bacterial membrane and are less sensitive to salt inhibition than many other known CAMPs. The alligator cathelicidin peptides were not hemolytic against sheep red blood cells at 300 μg/ml and were not significantly cytotoxic against A549 human lung epithelial cells after 24 h exposure in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. These alligator cathelicidin peptides have activity similar to other CAMPs from reptiles such as NA-CATH. It is possible that the alligator cathelicidins play an important role in the innate immune response of A. mississippiensis, similar to LL-37 in humans. In addition, due to their activities against MDR bacteria and lack of cytotoxicity, the AM-CATH peptides could be an attractive platform for further development as a potential therapeutic.

Study Information

Provider

pubmed

Year

2017

Date

2017-01-13T00:00:00.000Z

DOI

10.1016/j.dci.2017.01.011

Citations

61

References

75